Jonathan Kerr

Jonathan Ricardo Kerr, BSc, MBBCh, MD, PhD, FRCPath, is a British researcher who became interested in ME/CFS after studying the consequences of Parvovirus B19 infection and finding that some of those infected went on to develop CFS. Formerly of St. George’s University of London, he was working as an Associate professor in the School of Medicine and Health Sciences at Universidad del Rosario, Bogotá, Colombia. He has returned to the UK in 2018

Notable studies

 * 1997, Parvovirus B19 and Chronic Fatigue Syndrome (Abstract)
 * 2005, Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome (Full Text)
 * 2005, Association of chronic fatigue syndrome with human leucocyte antigen class II alleles (Full Text)
 * 2007, Review - Current research priorities in chronic fatigue syndrome/myalgic encephalomyelitis: disease mechanisms, a diagnostic test and specific treatments (Full Text)
 * 2008, Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (Full Text)
 * 2009, Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (Full Text)
 * 2008, Gene Expression Subtypes in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (Full Text)
 * 2010, Antibody to parvovirus B19 nonstructural protein is associated with chronic arthralgia in patients with chronic fatigue syndrome/myalgic encephalomyelitis (Full Text)
 * 2014, Use of single-nucleotide polymorphisms (SNPs) to distinguish gene expression subtypes of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) (Abstract)
 * 2016, Prevalencia de síntomas de fatiga crónica / encefalomielitis miálgica (SFC/EM) y su relación con factores ocupacionales en trabajadores en una empresa de vigilancia en Bogotá, Colombia (Jonathan Kerr) Note: This study did not use PEM as a inclusionary symptom nor did it use any Definitions of ME and CFS including the most symptom liberal of valid definitions, SEID. The only entry criteria noted were fatigue and muscle pain which seem to be the broadest and loose of symptom definitions Reeves criteria and Oxford criteria.
 * 2016, MicroRNAs hsa-miR-99b, hsa-miR-330, hsa-miR-126 and hsa-miR-30c: Potential Diagnostic Biomarkers in Natural Killer (NK) Cells of Patients with Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) (Full Text)
 * 2019, Review article - Epstein-Barr virus induced gene-2 upregulation identifies a particular subtype of Chronic Fatigue Syndrome / Myalgic Encephalomyelitis (Abstract)

Talks & interviews

 * 2014, Dr. Kerr, I presume?
 * 2015, Spoonie Radio - episode 14 - Jonathan Kerr

Invest in ME International ME Conference

 * 2006, Speaker at the 1st Invest in ME International ME Conference on Viral and Human Gene Expression, development of diagnostic test, news of clinical trials DVD available
 * 2007, at the 2nd Invest in ME International ME Conference on Case Study - Biomedical research (A view of a biomedical research team, how it is funded, what it needs, how it could be improved, what the future research would look like) DVD available
 * 2008, Speaker at the 3rd Invest in ME International ME Conference on Gene Expression in ME/CFS: a means of Subtyping DVD available
 * 2009, Speaker at the 4th Invest in ME International ME Conference on Severely-affected Sub Groups of ME/CFS DVD available
 * 2010, Speaker at the 5th Invest in ME International ME Conference on Study of SNPs to determine subtype status in CFS patients DVD available

Online presence

 * Invest in ME - Jonathan Kerr
 * PubMed - Jonathan Kerr

Learn more

 * Jonathan Kerr